Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Rember for Alzheimer's: Methylene Blue's Comeback | Main | Job Seekers: Genentech, GSK, and Elsewhere »

August 1, 2008

GSK Layoffs: Yes, Again

Email This Entry

Posted by Derek

The ax is falling again at GlaxoSmithKline. This time it’s the oncology group.

Last month the cardiovascular people got this same treatment, you’ll recall, and there was some disagreement about how many jobs were being affected. But it looks like the company is moving one by one through its Centers of Excellence in Drug Discovery (CEDDs) and running a most excellent scythe through them. By the time they’re through, the total number of layoffs looks like it will be substantial indeed.

That’s because inside each area so far the cutbacks are pretty sweeping. Total oncology head count is apparently being reduced by about 40%. Discovery chemistry seems, unfortunately, to be getting it a bit worse, since some of the sub-areas aren't losing head count at all. The estimates I have are that of the c. 120 chemists in the area, about 60 are losing their jobs. That includes the entire oncology med-chem group at the Research Triangle Park location, and from what I'm told, none of them are being relocated to the Philadelphia-area sites. So much for discovering Tykerb, et al.

Are all of the CEDDs going to get this same treatment, or to the same degree? GSK isn’t saying, but I’d certainly bet on this sort of thing happening again as the year goes on. What the company’s research arm will look like when it’s all over is anybody’s guess, too, but there’s one thing for sure: it’ll be a heck of a lot smaller.

And whether this new trimmed-down inlicensed/outsourced GSK will be any more productive is anybody’s guess either. But we won’t know that for a long time. It’ll take quite a while just for all of these changes to stop reverberating through the company, for one thing, and then it’ll be several years after that before it’ll be possible to look at the pipeline and have a majority of it be a product of the new organization. As I’ve said before, this is one the biggest challenges in trying to engineer a large-scale change in a drug discovery shop – the lag time before you see the effects.

I’m already seeing resumes, but I’d like to invite any readers who know of openings for experienced drug discovery positions to either mention them in the comments or email me about them for a future post. (I did a lot of that during my own experience with a site closure, but of course, this time I don’t know most of the people involved personally). At the rate things are going, I’m going to have to start running classified ads down the right side of the page.

Comments (53) + TrackBacks (0) | Category: Business and Markets | Cancer


COMMENTS

1. Petros on August 1, 2008 8:42 AM writes...

CNS (Harlow & Verona) got hit before Stevenage, partly due to the new Singapore/Shanghai effort.

Eastern England has taking a pasting in recent years with Merck closing HArlwo, UCB closing CAmbridge and significant cutbacks of both GSK CeDDs

Permalink to Comment

2. sharanya on August 1, 2008 9:00 AM writes...

Hi Derek.

I am a first year grad student in one of the MSKCC synthetic groups.. After coming to know about the GSK downsizing, I am glad am not graduating this year.. Though it might be worse 5-6 yrs down the line, no one can tell ! I am hoping that a synthetic chem card would prove useful for job-hunting.. !

Permalink to Comment

3. processchemist on August 1, 2008 9:08 AM writes...

I can't find a word about bodycount in Harlow and Verona...

Here there's an interesting link:

http://www.rsc.org/chemistryworld/News/2008/June/11060802.asp

Most notable of all:
"Despite the cuts, both Ley and Bains say there is still strong demand in the UK for good chemists - although both stress the need to be innovative and creative in their thinking and approach to the job"

What a creative approach means is clearly explained:

"Chemists will have to be creative about finding jobs, both in terms of the industry and geography"

Tragic or hilarious? Choose your own...

Permalink to Comment

4. The Pharmacoepidemiologist on August 1, 2008 9:08 AM writes...

Derek, the flow of resumes from GSK can not compare with the flood of them from the good folks at Genentech now inundating every biotech on the peninsula. The last week has been just unreal. Hearing the same thing from friends at other companies.

Permalink to Comment

5. Harlowmedchem on August 1, 2008 9:35 AM writes...

Around 75 chemists will go in Harlow.

Permalink to Comment

6. Anonymous on August 1, 2008 9:40 AM writes...

In WSJ blog a couple days ago:

http://blogs.wsj.com/health/2008/07/30/hey-drug-resarchers-lotsa-luck/#more-3064

"Just today we talked about R&D with GlaxoSmithKline’s newish CEO Andrew Witty, who was visiting New York. The problem in drug discovery and development isn’t the technology, he said, but a misunderstanding about the enterprise itself. “Drug discovery is not a process,” he emphasized. Finding new drugs takes an eclectic mix of serendipity, scientific judgment, good decision-making and focus."

Repeat of comment made there: Witty is correct that is not a process but drug discovery has been treated that way for many years by execs/managers that know little and care less about what R&D does. Focus on Marketing, Profits and M&As have lead to many failed decisons that side tracked innovation by science groups. Lean is good idea but some cuts (are) to the bone and need an organization with a complete view and wide functional areas or will never be able to translate the bench research into patient treatments.

At the same time I still think GSK are building up Research in China- maybe hoping those groups will be luckier as don't think will have the expertise for a while (and the top-down management of R&D has largely yielded the situation currently being critizied for lack of innovation).

Permalink to Comment

7. Anon on August 1, 2008 9:47 AM writes...

30-40 jobs will go in Verona (minimal compared to the 165 jobs in Harlow). The Verona site has had a strike about it and their unions are still contesting it.

Permalink to Comment

8. processchemist on August 1, 2008 10:30 AM writes...

#7

so in Harlow the cuts are 165 or about 70?
Still with an extended search, also in italian, I failed to find a word about the cuts or the strike.

Permalink to Comment

9. Kay on August 1, 2008 10:34 AM writes...

I was just looking at my C&E News, and I noticed GSK has a big ad in the job section, saying they are looking for "synthetic organic chemists". Kind of startled me, since I was part of the layoffs in PA.

Permalink to Comment

10. Hap on August 1, 2008 11:46 AM writes...

Kay: I hope this isn't mean (I don't mean it so) but maybe they're doing the "Circuit City" model of drug development - "If we just get rid of all the people making $X/year and replace them with people making $0.5X/year, we'll make more money...." That worked out really well for CC - all the good people know to go somewhere else, and the bad people know as long as they don't suck enough to get fired and aren't good enough to get pay raises to the death line, they have a job. Their stock price pretty much showed how well that reasoning went over.

I'm sure that'll work out well for future drug development at GSK.

Permalink to Comment

11. Not the smartest guy in the room on August 1, 2008 12:28 PM writes...

From the CEO of GSK, Andrew Witty, latest Q&A:
Q: What is the company’s overall direction with regard to chemists? Will the yearly increase in outsourcing continue? What is the future of small molecule drug discovery within GSK?
A. First, let me be clear on outsourcing. We hear a lot about the benefits of outsourcing – and of course there are many to be gained. However, you have to be strategic about what you outsource. The key question for me is; does outsourcing create value? If it does, we should consider it and when we do we should stop doing that work in-house. You might be surprised by the number of examples I have found where we have outsourced a process or activity but then, because we do not seem to trust the outsourcing company, we continue to monitor the chosen partner in such a heavy way that we may just as well have kept the work in-house!

In terms of chemistry, it is critical that our molecules are world class and that depends on our chemistry skills. It’s clear that chemistry is a key strategic capability. We are looking at ways of ensuring that the quality of our chemistry (and our chemists) remains at the highest level. Good chemists are hard to find and we need to retain and develop them. Small molecule chemistry and chemists are still vital incredibly important to the future of this company’s R&D.

Permalink to Comment

12. RKN on August 1, 2008 12:52 PM writes...

I'd be highly suspicious of the CEO's so-called key question: "Does outsourcing create value?"

The bottom line in these sweeping layoffs is that the company no longer has to match 401ks, pay health insurance for the employee and his/her family. They no longer have to fund vacation pay, sick leave, or pay for training, seminars, conferences, etc., plus all the travel involved. Or fund pensions and such, assuming the company still does that.

In essence laying off lots of people significantly reduces the costs involved with having to manage people. And if Big Pharma is managed anything like Big Oil is, where I worked, those expenses aren't insignificant. Outsourcing and contracting pushes the liability for these expenses onto someone else. My guess is that's the real motivation behind these layoffs, or at least a big one.


Permalink to Comment

13. Anon on August 1, 2008 2:29 PM writes...

#8

>165 jobs will go at Harlow, of which 75 are chemists.

Permalink to Comment

14. Anon on August 1, 2008 2:34 PM writes...

#8 There are going to be 30-40 job cuts at Verona from the Neurosciences (former psychiatry) CEDD. The strike was a half day strike where most people stayed at home. Why is there any reason to doubt this? It is a fact. I don't believe GSK themselves are in the habit of publicisising jobb cut details about individual sites, or indeed strikes!

Permalink to Comment

15. CMC guy on August 1, 2008 2:46 PM writes...

#11 ntsgitr do you have a cite/link for these comments by Witty? Would appreciate context and likely other comments. thank you

Permalink to Comment

16. chemistdude on August 1, 2008 3:55 PM writes...

#11 were in a Q&A session posted by Andrew Witty on his area of the GSK intranet. A chemist (From UP?) has sent this question via the link.

Permalink to Comment

17. anon on August 1, 2008 3:58 PM writes...

#15: This was published on an internal website, and both parts of the statement are reproduced exactly as we saw it.

Derek: Thanks for encouraging potential employers to publicize their job openings through your site! The (very few) internal openings closed up quickly after the CVU purge, so the rest of us are out in the cold if layoffs happened within our CEDD. Our CEDD was told that we would have more information about the budgets towards the end of the year (november), and I expect that other CEDDS may be in similar situations.

Permalink to Comment

18. CMC guy on August 1, 2008 4:58 PM writes...

#16/17 thanks for clarification and peek into GSK. As outsider I am not sure what to make of Witty yet- many things he says make sense however company actions of late seem at times to run counter to statements (and truism actions speak louder than words). Sure feel for those insider (or formerly so) as likely a tense situation. Unfortunately as Dereck points out it takes a long time to see results.

Permalink to Comment

19. Anonymous on August 1, 2008 5:16 PM writes...

Genentech still has several senior med chemist positions open. Obviously there is some uncertainty with the Roche deal, but the claim is that research will be untouched and we aren't waiting until any deal closes to fill these positions.

Permalink to Comment

20. CC on August 1, 2008 5:46 PM writes...

Derek, the flow of resumes from GSK can not compare with the flood of them from the good folks at Genentech now inundating every biotech on the peninsula.

This just makes no sense to me. If you're so attached to today's Genentech, it seems like the closest thing out there is going to be Roche's Genentech. Why would you rush out to join some random biotech, if that wasn't an attractive option last month?

Sympathy and luck to all the affected GSK people...

Permalink to Comment

21. chemist on August 1, 2008 10:07 PM writes...

Having worked in medicinal chemistry, at several companies over the last 15 years, it's obvious to me why they are canning so many people. The clowns who work in these places are ridiculous, they have no mind for productivity, how to increase throughput in discovery, how to use of automation and modern instrumentation etc. (without forking over 150K to agilent per instrument and never even putting the damn thing to use) It's laughable. I welcome the cull that's going on, get rid of all these old school idiots, they're worthless. Things will not move forward again until we stop working like some archaic graduate lab.

Permalink to Comment

22. Hap on August 2, 2008 12:45 AM writes...

Problem is, the "old-school idiots" were the only ones to actually come up with working drugs - if the new people were able to enhance productivity so much, you'd figure that someone (either at the big companies or at smaller ones) would actually be making and selling new drugs, and there wouldn't be any need for the purges, because there would be plenty of money to go around. Alas, that doesn't seem to be the case.

Permalink to Comment

23. processchemist on August 2, 2008 2:05 AM writes...

@#14
I have no doubts about the strike: I only register the complete blackout about it on the national and local press.

Permalink to Comment

24. Oracle on August 2, 2008 11:00 AM writes...

I think people are forgetting GSK (like everyone) is expanding operations in China. So long as you outsource your R&D base, this will continue. Management is in the maximum profit biz, not the drug biz. If they could convert the labs into shoe factories at higher profit margins they'd do it. An organic chemist in the USA is akin to a sail seamstress in the late 1800's. You might have advised 'Apple Annie' diligently knitting her sail to knit faster or use high-tech needles to improve her productivity. The reality is her livelihood is doomed. Hopefully (and this is a slim hope), we'll see a fresh bout of unionization in the industry in the future. This will allow the handful of jobs remaining to have some clout.

Another possibility is a week-long strike nation wide to protest. Since most scientists have timid personalities I don't think this likely.

Permalink to Comment

25. Jason on August 2, 2008 4:39 PM writes...

This reminds me of a conversation I had with a VC - he said oncology had been overinvested in (at least among VCs) I wonder if GSK had the same idea at decided anything they discovered would face stiff competition from VC-backed biotechs?

BTW, it seems like CV is an area with not too much potential (at least commercial potential) - so why keep scientists busy there?

Permalink to Comment

26. scooter on August 2, 2008 5:12 PM writes...

I agree with oracle. I went through this in the computer industry. I don't think the real problem is so much that outsourcing is such a winner- it's management's lack of will to invest in anything. Management is not graded on improving the company long term- they want to have a few good quarters and parachute out. They go with whatever is cheaper. Its happening in a lot of industries besides this one.

Permalink to Comment

27. anon on August 3, 2008 8:52 AM writes...

#24: Yes, I do feel that American organic chemists are not helped by the quite extensive outsourcing to China. It seems that the Chinese plan is to monopolize the industry by charging a cheaper price for services, but they will eventually decide that they want more $ as well. I can see this starting to happen already, take for instance Wuxi. Of course, the Chinese people would have gotten foreign industry to build all of the necessary infrastructure in their country by this time as well. Maybe with our falling dollar, this will play out that in 5-10 years it will be cheaper to make stuff in the US again. If not, the companies will probably look into another coutry with a large availability of intellegent cheap labor. Bottom line: it is all a gamble from our standpoint and it is hard to work with an axe constantly hanging over your head ready to strike. No, I'm not all "doom and gloom," just realistic.

Going back to the other definition of strike: I don't think that it is such a good idea to pursue this line of reasoning. If Americans cause problems for the company by organizing strikes (bad publicity!), then it will just make it easier for them to decide to move jobs elsewhere. In other words, forming unions and striking would most likely lead to even more job loss instead of protecting us. Remember, big pharma hires good lawyers (better than any of us could afford on our own).

My advice to the American chem students reading this: learn from the situation that your "elders" are in and carefully consider if you want to live like this.

Management cares primarily about pleasing their stockholders, and the pharma industry as a whole is under alot of pressure from the government and other organizations to keep prices down. Therefore, management is going to try to find the cheapest cost of goods possible to ensure that there is a sufficient profit margin to please the stockholders (and make sure that the managers each have a new Porsche). Labor/"people costs" is a huge expense for any company, so it is easy to target.

Yes, I realize that it was also bad in the 1990's, but the situation now seems like it is less resiliant than it was back then. Companies built infrastructure in foreign countries that was not present back then, and want a return for their investment. Remember also that some areas of research are very controversial here, but can be run routinely in China. A prime example is the stem cell research programs.

Good luck to my current and past colleagues. It is a brave new world, and I certainly was naive about this happening when I went to grad school.

Permalink to Comment

28. Anonymous on August 3, 2008 11:32 AM writes...

#21 Chemist - You sound just like my former director...Thought all of us with 15+ years actual experience where fossils because we didn't automatically embrace expensive non proven technologies, and actually used our brains... This same director that had no real med-chem experience... Proposed working on screening hits that anyone with any experience could see were probably binding multiple degradation products rather than the target compound.. That's how unstable they where...

This was really a ploy to remove expensive resources.... Same director targeted almost everyone over 35 without a PhD degree with you are obsolete.. Lets face it - its easier to and cheaper to hire fresh faces that won't argue with you.

#22 Hap - You are right on.. In fact I knew quite a few old school med chemists one of which was involved in research that got not one but 2 drugs out into the market place. I will also add that he had only a BS degree and 30+ years experience and won the Chairman's Award for excellence. It was sad to see however what the new younger generation managers did to him in his later years prior to retirement. His experence ended up counting for nothing.


Permalink to Comment

29. James on August 3, 2008 2:40 PM writes...

As for Anon #27, I wouldn't hold my breath on waiting for China's currency differential to narrow to the point that it is more cost effective to carry out research here in the US. As products from China become more expensive due to the combination of a depreciating dollar and rising Yaun, it makes EVEN MORE sense to carry out research in China due to the savings in insurance, no EPA crap or worker safety etc. Remember we don't make much in the USA anymore.
So long as chemists are treated as global commodities, a career in the US is impractical for the average citizen. Temporary visas (of which it is well know the caps have not been enforced), allow all the other 6 billion inhabitants of the planet earth a crack at an American Job. It's also good for preventing any kind of worker organization. That's probably the real reason why Americans are tossed in the wood chipper.

Permalink to Comment

30. anon #27 on August 3, 2008 3:49 PM writes...

James: As an American, I agree that chemists being viewed as "global commodities" is generally not beneficial for American jobs. Service based jobs, with some exceptions (IT service that can be outsourced to India), seem to generally be a better choice for an American to pursue in this global economy.

It is also true that the Chinese have a historical reputation for being lax with their safety standards as well as mistreatment of the environment (and, in some cases, their people), but I don't think that this approach can be maintained indefinately.

China certainly spent alot of effort to clean up Beijing in preparation for the Olympics. Reader's Digest has an interesting story on these efforts, and the (American?) author claims that the area of China where he resides now is starting to closely resemble an American city in some respects. China has Burger Kings and Wal-Marts, and some Chinese are purchasing Hummers and large Buicks. The Chinese people have seen what Americans sometimes take for granted and also want an higher standard of living.

Permalink to Comment

31. Asteroid Fan on August 3, 2008 4:04 PM writes...

OK, NOW I understand why the price of my GLAXO Dex Spansules went up $150 in almost a month.(So it isn't my ADD-addled brain that has noticed some problems WRT homogeneity lately.) And of course, most insurance plans will not cover (or only partially) these meds produced from unicorn horns.

Look, I am not against good 'ol capitalism and making a profit. But the next time I hear about the "failure" of bioresearch in the US or if some whiner wants to know why cancer or AIDS, etc. hasn't been cured, I'll smack them upside their head with the rock they've been living under for the past 20 yrs. And I'll ask them why so many students have chosen that MBA (+ all the 'fixins) over attending college for at least 10 yrs ("There's a hole in my pocket dear Liza...") and scrambling for that "lucrative" $30,000 post-doc slot. But they won't hear a word 'cuz they're watching their fav foot/base/basket-ball player who will make 6 or 7 big bills even if they don't play a minute. So when they're pacing some hospital pediatric floor and the attending doc is just about out of ideas and/or meds, they can call one of those "players" (MBA, NFL, etc). I'm SURE they'll come up with the cure.

Permalink to Comment

32. processchemist on August 4, 2008 2:41 AM writes...

@#27

>It seems that the Chinese plan is to monopolize
>the industry by charging a cheaper price for
>services, but they will eventually decide that
>they want more $ as well

Ehi, it's what chinese do best: state-assisted dumping. And not only in our field.

Permalink to Comment

33. DM on August 4, 2008 6:41 PM writes...

Interesting subjects here about GSK and the article. All Pharma's are going towards China for business. If you can speak the language then you have it made especially at GSK, otherwise you are on the fence just like everyone else.

One thing GSK need to clean up is the number of outsource vendors, who create more maintance work for full-time people. Outsource workers and consultants know how to abuse GSK $ resources and do a good job of it! The sad thing is most internal fulltime folks know it, but are just trying to keep their head above water so they let allot of issues go!

GSK CEDDs really need to take a good look at Outsource workers and consultants abusing GSK before they address further cuts of fulltime employees in Philadelphia and RTP.

Permalink to Comment

34. anon on August 5, 2008 10:42 AM writes...

China is like combo was 15 years ago. It's not going away, but it's also not a viable replacement for real R&D.

And who's to say our Government won't eventually get a clue and start adding a surcharge on ex-Asia goods to make up for the lack of environmental / labor standards there? I sure would.

Permalink to Comment

35. Zoom on August 5, 2008 4:53 PM writes...

GSK is closing the Oncology Chemistry group in RTP because they have been too successful in delivery a lot of candidates that choke the pipeline. And the new management is rewarding them big time (punishment for sustaining the pipeline)...Senoir management just handed the group that made the candiate for the project they are really excited about and they even want to fast track it. Never fill your companies pipeline...just make attempts to. You see, most of these senoir management have a very short life span with the company so why the chemist is working hard for the oppotunity to retire in the far future...they (SVPs) will fail in three years and be moved to another department or kicked out...therefore, they plan for the short term...3 years. RTP Oncology Chemistry has given them more than enough to make management look good for their short term...3 yrs. Why will they keep you to make contributions to long term goals they will not be part of.

Here is the irony...GSK has a 10 year plan to GSK China R&D and a 3 year plan for all the new fancy small is beautiful DPUs.

As for the ACS, the least said about them the better.

Permalink to Comment

36. momrowgal on August 5, 2008 8:49 PM writes...

Asteroid Fan, your final paragraph is the greatest thing I've read in a long time. What a sacred cow spectator sports have become--it seems that we've lost the capacity for any kind of rational thought when it comes to measuring costs and benerits.

Permalink to Comment

37. GSK RTP fading fast on August 5, 2008 9:13 PM writes...

There will be no improvements / efficiency.

The goal of these cuts is simply to reduce internal headcount in 'high cost' regions (US/UK).

GSK will now be spending 50% of its R&D budget on buying-in projects and products.

These recent cuts are only the tip of the iceberg. At present only the 'research' jobs are being cut. The ripple effect (Tsunami?) will spread to all of the groups that support research. The Development groups in particular (who receive their projects from Research) are next. Their workload has already dropped drastically since the previous cuts in Research were made and everyone is expecting much, much more cuts. Everyone in PharmDev and ChemDev have been told that they will all be consolidated from the various buildings they now occupy into one building. There simply isn't room for that to take place unless >% of PharmDev and ChemDev are cut. That consolidation is scheduled to take place by the end of this year. There is also speculation of an entire site closure (RTP) being done over a period of 1-2 years.

Permalink to Comment

38. Left out the ">50%" cuts from previous post on August 5, 2008 9:17 PM writes...

There will be no improvements / efficiency.

The goal of these cuts is simply to reduce internal headcount in 'high cost' regions (US/UK).

GSK will now be spending 50% of its R&D budget on buying-in projects and products.

These recent cuts are only the tip of the iceberg. At present only the 'research' jobs are being cut. The ripple effect (Tsunami?) will spread to all of the groups that support research. The Development groups in particular (who receive their projects from Research) are next. Their workload has already dropped drastically since the previous cuts in Research were made and everyone is expecting much, much more cuts. Everyone in PharmDev and ChemDev have been told that they will all be consolidated from the various buildings they now occupy into one building. There simply isn't room for that to take place unless >50% of PharmDev and ChemDev are cut. That consolidation is scheduled to take place by the end of this year. There is also speculation of an entire site closure (RTP) being done over a period of 1-2 years.

Permalink to Comment

39. MedChem on August 6, 2008 4:36 AM writes...

Something similar happened in the UK. The UK ID CEDD site had alot of the Avandia team there (From former MV CEDD Virology), and the antibac group had just launched Altabax onto the market. Their reward was a severance check in the post! Good to see they are now being consistent with the RTP Oncology group!
I've often wondered if it's a stats game: every med. chem. group is likely to discover one drug in their career, therefore once they've discovered one, get rid of them and keep the unsuccessful ones because they're more likely to yield a drug!

Permalink to Comment

40. jose on August 10, 2008 5:16 PM writes...

Jose

Man man, GSK is now laying off their virology group at RTP now. Of course, for obvious reasons-lack of productivity. Eight years of metabolic and virology research and not a dime in the pocket!!

Permalink to Comment

41. paul on August 12, 2008 10:23 AM writes...

"There will be no improvements / efficiency.

The goal of these cuts is simply to reduce internal headcount in 'high cost' regions (US/UK).

GSK will now be spending 50% of its R&D budget on buying-in projects and products."

Nice comment - on the money too.

Even in Oncology MDC the push is to outsource clinical studies en bloc. so they are cutting staff. Mainly US as it is considered more high cost and easier to cut than UK which is covered by contract.

Oh an do not look only at China - GSK also has a build out planned for India that includes an R&D presence and Management presence. - low cost as well. It was Moncef's plan and unless Witty changes it

Permalink to Comment

42. RTP (for now...) on August 12, 2008 10:04 PM writes...

What have you heard about cutting virology in GSK-RTP?

I was under the impression that they did their cuts several months back.

Is something new brewing?

Permalink to Comment

43. jose on August 13, 2008 9:07 AM writes...

jose,

I would not assume that just beacause they did a few cuts they are going to stop there. The folks at RTP have gone through 3 reorgs in the last 18 months, its not over as yet. With the unexpected gloomy outlook for their HPV vaccine based on Merck's revenue-it would be hard to justify keeping an unproductive site

Permalink to Comment

44. Anon on August 14, 2008 3:49 AM writes...

The HPV vaccine is a biopharm CEDD product, not virology.

Permalink to Comment

45. More GSK -RTP layoffs in Sep/Oct on August 16, 2008 2:22 PM writes...

Everyone in RTP PharmDev/ChemDev/I.T. is saying the same thing. They're expecting a major re-org and layoffs within a month or so.

Also there is roumer that the UM/UP PharmDev pilot plant will be down-graded from GMP to development only. With GMP work moving to RTP pilot plant, which has just been approved for a 1.2 million dollar upgrade.

Permalink to Comment

46. Anonymous on August 23, 2008 3:17 PM writes...

GlaxoSmithKline establishes Global Drug Development support centre with Tata Consultancy Services
GlaxoSmithKline (GSK) and Tata Consultancy Services announced an agreement to establish a global drug development support centre in Mumbai to help meet the demands of the growing GSK pipeline.
Under a multi-year multi-million dollar contract agreed by the two companies, TCS will provide a variety of services in clinical research, including Clinical Data Management and Clinical Submissions Support. The partnership will help GSK expand capacity in response to increased efficiency demands, leverage the high-quality talent pool in India, and benefit from cost and process improvements.
The centre will house a TCS team of highly skilled professionals including pharmacologists, PhDs in life sciences, post-graduates in Pharmacy, and individuals with a life sciences background experienced in clinical-data management and programming. TCS will bring in its strong domain expertise, superior talent management skills, flexible operating models, proven transition capabilities and performance driven processes.

"This strategic partnership with TCS represents a significant step towards GSK's vision of leveraging key talent globally to develop innovative medicines, said Dr. Amber Salzman, Senior Vice President, Development Operations, GSK. “GSK has chosen to partner with TCS because of its strong record in knowledge process outsourcing, underpinned by operational excellence. I am confident our collaboration will benefit both partners and, most important, help to deliver new medicines to patients."
GSK, whose presence in India dates from 1924, is the leading research-based pharmaceutical company in the country by sales. The pharmaceuticals business of GSK India employs 2425 people.
Commenting on the partnership, J. Rajagopal, Executive Vice President and Global Head- Life Sciences & Healthcare, TCS said: "The engagement with GSK is an endorsement of TCS's strategy to focus on services supporting the drug development processes and the investments made in building our domain competencies in this area. The opportunity to work with GSK will further enhance our capabilities across therapeutic areas and help us build a long term relationship with an acknowledged industry leader."
VK Raman, Head, TCS BPO added: “TCS looks at areas to develop a KPO business that leverages IT to provide a transformational customer experience both from a performance and cost standpoint. The life sciences space provides an important opportunity to implement that strategy and the partnership with GSK will help drive competencies and skills in this fast-growing segment.”
The Life Sciences and Healthcare Practice at TCS has over 3200 professionals including pharmacologists, physicians, biomedical engineers, biostatisticians, ICH/GCP compliance professionals, GxP consultants, PhDs, IT architects, consultants and management graduates who are focused on providing best in class IT consulting, solutions and services to Life Sciences and Healthcare customers across the world.
TCS' Life Sciences services cover the entire spectrum of R&D and, TCS works with a number of leading pharmaceutical and healthcare companies across the value chain. The Practice has an impressive list of clients, which includes highly reputable multinational organizations.
- End -
About GlaxoSmithKline (GSK)
GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For company information, visit GlaxoSmithKline at www.gsk.com
About Tata Consultancy Services Ltd (TCS)
Tata Consultancy Services Limited (TCS) is the world leading information technology consulting, services, business process outsourcing and engineering services organization that envisioned and pioneered the adoption of the flexible global business practices that today enable companies to operate more efficiently and produce more value. TCS achieved this by creating and perfecting a unique method of global deployment and delivery of high quality, high value services and products in IT consulting and business process outsourcing. Known as the “Global Delivery Model,” this strategic services delivery concept has reshaped the IT services industry.

More than 95% of TCS customers reward the company's reliability, passion, creativity, and unique ability to handle the broadest range of their IT needs by continually extending and deepening their partnerships with TCS. With over 70,000 of the world's best trained IT consultants located in 35 countries, TCS is uniquely positioned to deliver its flexible world class services seamlessly to any location. TCS reported consolidated revenues of $2.97 billion (U.S.) in the fiscal year 2005-2006. The company is listed on the National Stock Exchange and Bombay Stock Exchange in India.

GSK inaugurates its technical development centre in Nashik
Posted by admin on Sunday, June 15th 2008

GlaxoSmithKline (GSK) launched its technical development centre in India. This is GSK’s new state of art technical development centre in India. It is intended to cater to the international market for pharma evaluation by utilising the expertise of highly skilled Indian scientists and engineers, with

the latest computerised facilities, conforming to international standards. The centre was inaugurated by Jean-Paul Reynaud, SVP, Regional Pharma Supply in the presence of Kay-Yong Tan, Vice President, India and China sourcing supply and Dr Ashoke Banerjee, Executive Director, GSK India. The centre will develop knowledge in the form of process and product understanding by utilising design of experiments, chemometrics and other lean sigma tools. The new center will support the development of solid, liquid and semisolid dosage forms alongwith analytical and packaging enhancements.

This center will cater to the needs of global GSK manufacturing units in order to provide better service to the ultimate customer by improving the quality of product and ensuring security of supply.

Permalink to Comment

47. More layoffs coming to GSK on September 3, 2008 9:11 PM writes...

Preclinical Development in GSK has been given the first official hint of more lay-offs.

A 'need for change' memo was sent ount to all of PCD refering to need to 'shift resources'

More official news is to follow late Sept...

Permalink to Comment

48. Anonymous on September 24, 2008 9:34 AM writes...

I'm in Pharm Dev at UM/UP. My management is basically telling us to look, and we are getting our PDP's together for final review.

We're expecting major announcement early next week from John giving more light on "major cuts."

Given all our group has delivered, it's coming as a real shock. As far as the economy goes, these layoffs couldn't be happening at a worse time for all of us.

Permalink to Comment

49. Anonymous on September 30, 2008 7:24 PM writes...

just FYI, I was part of a severe cut in MDR, today.

Permalink to Comment

50. Anonymous on September 30, 2008 7:37 PM writes...

Sweeping layoffs across MDR (including me) today. I imagine that many of our CEDD...er... DPU customers will be unhappy to know that we can no longer support their projects. I'm sure MDR IT is next.

Permalink to Comment

51. Anonymous on October 8, 2008 5:44 PM writes...

Alot of cuts came from Oncology CEDD on Tues Oct 7 and Wed Oct 8. Alot of people are left reeling and there is no rhyme or reason with respect to the people who were retained.

Permalink to Comment

52. LayoffGossip on January 12, 2009 7:09 AM writes...

People always hate to talk about when they are laid off. But as it has become every day's news headline since Yahoo started it with cutting 1500 of its task force last year, now a need of platform has been in demand where people can express their selves in words how they are feeling about their company, whey the got laid off was that justified or not.
And every thing they want to tell anonymously.And www.layoffgossip.com is providing you that platform.

Permalink to Comment

53. flyonthewall on July 28, 2009 12:08 PM writes...

My friend works in a GSK QC lab. Last month my friend reported a colleague for fraudulent behaviour. Since then, my friend has been suspended and the cover up is in full swing.
This site is undergoing major downsizing, completion early 2011.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Scripps Update
What If Drug Patents Were Written Like Software Patents?
Stem Cells: The Center of "Right to Try"
Speaking of Polyphenols. . .
Dark Biology And Small Molecules
How Polyphenols Work, Perhaps?
More On Automated Medicinal Chemistry
Scripps Merging With USC?